Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biogen’s $7.3 Bln acquisition of Reata followed bidding war

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Aug 14, 2023 3:45pm

238 Views

Post# 35587617

RE:RE:Biogen’s $7.3 Bln acquisition of Reata followed bidding war

Agreed Note. The information Oncy advanced that more BPs are interested since ASCO was just what the Dr ordered. Something that they obviously can't divulge is going on. Who was the institution that took up most of the $15m bought deal? Sept & Oct will be exciting & could bring the long awaited acquisition of Oncy.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas